Gossamer Bio IncNASDAQ:GOSSNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.5624
- TODAY'S CHANGE (%)0.0140 (2.5529%)
- Bid / Lots0.5561/ 2
- Ask / Lots0.5759/ 8
- Open / Previous Close0.5700 / 0.5484
- Day Range
- 52 Week Range
- Volume21,222
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | GOSS |
|---|---|---|
| 09:32 ET | 11368 | 0.58205 |
| 09:34 ET | 6967 | 0.5624 |
Jun 7, 2024
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4), from 4:30PM ET on Friday Jun 07, 2024 by Dow Jones
4:30PM ET on Friday Jun 07, 2024 by Dow Jones
May 20, 2024
DJ Gossamer Bio Price Target Maintained With a $10.00/Share by HC Wainwright & Co., from 11:20AM ET on Monday May 20, 2024 by Dow Jones
11:20AM ET on Monday May 20, 2024 by Dow Jones
May 14, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Gossamer Bio Inc | 129.6M | -0.5x | --- |
Tevogen Bio Holdings Inc | 129.0M | -1,839.5x | --- |
Vigil Neuroscience Inc | 127.0M | -2.2x | --- |
Context Therapeutics Inc | 133.5M | -1.3x | --- |
aTyr Pharma Inc | 125.6M | -2.2x | --- |
Cardiff Oncology Inc | 133.3M | -3.3x | --- |
Company Information
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH). Its product candidate Seralutinib, also known as GB002, is an investigational inhaled, small molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. In contrast to the three classes of marketed vasodilatory therapies for PAH, its seralutinib has the potential to reverse pathological remodeling by addressing mechanisms that underlie PAH. Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways. In addition to PAH, seralutinib holds the potential as a therapeutic option for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Contact Information
- Headquarters
- 3013 Science Park RdSAN DIEGO, CA, United States 92121-1101
- Phone
- 858-922-0718
- Fax
- 302-636-5454
Executives
- Chairman of the Board, President, Chief Executive Officer, Co-Founder
- Faheem Hasnain
- Chief Operating Officer, Chief Financial Officer
- Bryan Giraudo
- Executive Vice President - Regulatory
- Caryn Peterson
- Executive Vice President - Technical Operations and Administration
- Christian Waage
- Chief Medical Officer
- Richard Aranda
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $129.6M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 226.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.86 |
EPS | $-1.05 |
Book Value | $0.28 |
P/E Ratio | -0.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
